Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Boehringer deal, clinical milestones support Bridge IPO

Deal with Boehringer, pending first-in-class readouts help Bridge raise $36M in KOSDAQ IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs.

The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate first-in-class molecules discovered in Asia resonated with investors as the company raised W42 billion ($35.8 million) through the sale of 700,000 shares at W60,000 per share in an IPO on KOSDAQ that valued

Read the full 683 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE